Literature DB >> 10509674

Enhanced secretory group II PLA2 activity in the tears of chronic blepharitis patients.

C H Song1, J S Choi, D K Kim, J C Kim.   

Abstract

PURPOSE: Phospholipase A2 (PLA2) hydrolyzes phospholipids, one of the important constituents of human meibomian gland secretions. This study was performed to investigate PLA2 type and activity in the tears of chronic blepharitis patients compared to those of normal persons.
METHODS: Tear samples of 36 patients and 10 normal persons were collected in non-heparinized microcapillary tubes. PLA2 activity in the tears was measured by Dole's method, and the results of the blepharitis patients were compared to those of the normal persons. The characterization of PLA2 was performed by the head group preference test and the dithiothreitol (DTT) sensitivity test. The classification of PLA2 type was done using Western blot analysis with anti-human secretory PLA2 antibody.
RESULTS: No statistically significant differences were found among the six categories of chronic blepharitis. However, the mean PLA2 activity in the tears of the chronic blepharitis patients was about two times higher than that of the normal controls with statistical significance (P < 0.05). The PLA2 substrate specificity test revealed group II PLA2 activity. Furthermore, the group II PLA2 was identified as a 14 kDa band in Western blot analysis using an antibody raised against human secretory group II PLA2.
CONCLUSIONS: Secretory group II PLA2 activity was significantly enhanced in the tears of the chronic blepharitis patients compared with that of the normal controls. It is suggested that this increased enzymatic activity may decrease the tear film stability through increased hydrolysis of phospholipids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10509674

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

Review 1.  The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee.

Authors:  Penny A Asbell; Fiona J Stapleton; Kerstin Wickström; Esen K Akpek; Pasquale Aragona; Reza Dana; Michael A Lemp; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 2.  [Blepharitis component of dry eye syndrome].

Authors:  C Auw-Hädrich; T Reinhard
Journal:  Ophthalmologe       Date:  2018-02       Impact factor: 1.059

3.  Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16.

Authors:  Yuichi Hori; Sandra J Spurr-Michaud; Cindy Leigh Russo; Pablo Argüeso; Ilene K Gipson
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-11       Impact factor: 4.799

4.  Longitudinal changes in tear fluid lipidome brought about by eyelid-warming treatment in a cohort of meibomian gland dysfunction.

Authors:  Sin Man Lam; Louis Tong; Xinrui Duan; U Rajendra Acharya; Jen Hong Tan; Andrea Petznick; Markus R Wenk; Guanghou Shui
Journal:  J Lipid Res       Date:  2014-07-03       Impact factor: 5.922

5.  Proteomic analysis of human meibomian gland secretions.

Authors:  P S Tsai; J E Evans; K M Green; R M Sullivan; D A Schaumberg; S M Richards; M R Dana; D A Sullivan
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

6.  sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised.

Authors:  Dongmei Chen; Yi Wei; Xiaohong Li; Seth Epstein; J Mario Wolosin; Penny Asbell
Journal:  Exp Eye Res       Date:  2008-12-16       Impact factor: 3.467

7.  Meibum lipid composition in Asians with dry eye disease.

Authors:  Sin Man Lam; Louis Tong; Siew Sian Yong; Bowen Li; Shyam S Chaurasia; Guanghou Shui; Markus R Wenk
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.